Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis

Adriano Chiò, Edward R. Hammond, Gabriele Mora, Virginio Bonito, Graziella Filippini

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background Staging of disease severity is useful for prognosis, decision-making and resource planning. However, no commonly used, validated staging system exists for amyotrophic lateral sclerosis (ALS). Our purpose was to develop an ALS staging system (ALS Milano-Torino Staging) that captures the observed progressive loss of independence and function. Methods Clinical milestones in ALS progression were defined by loss of independence in four key domains on the ALS Functional Rating Scale (ALSFRS): swallowing, walking/self-care, communicating and breathing. Stages were defined as follows: stage 0, functional involvement but no loss of independence on any domain; stages 1-4, number of domains in which independence was lost; and stage 5, death. Staging criteria were applied to patients enrolled in a Quality of Care in ALS (QOC) study; endpoints included function (ALSFRS), quality of life (QOL; Short Form-36) and health service costs. Between-stage transition probabilities were assessed in the QOC study and in a second clinical study of lithium carbonate in ALS. Results 70/118 (59.3%) participants in the QOC study progressed to higher stages of disease at 12 months compared with their baseline stage. Functional (ALSFRS) and QOL measures were inversely related to disease stage. Health service costs were directly related to increasing disease stages from 0 to 4 (p

Original languageEnglish
Article numberA10
Pages (from-to)38-44
Number of pages7
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume86
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Amyotrophic Lateral Sclerosis
Health Care Costs
Health Services
Lithium Carbonate
Quality of Health Care
Deglutition
Self Care
Evaluation
Walking
Decision Making
Respiration
Quality of Life
Rating Scales

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Arts and Humanities (miscellaneous)
  • Medicine(all)

Cite this

Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. / Chiò, Adriano; Hammond, Edward R.; Mora, Gabriele; Bonito, Virginio; Filippini, Graziella.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 86, No. 1, A10, 01.01.2015, p. 38-44.

Research output: Contribution to journalArticle

Chiò, Adriano ; Hammond, Edward R. ; Mora, Gabriele ; Bonito, Virginio ; Filippini, Graziella. / Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. In: Journal of Neurology, Neurosurgery and Psychiatry. 2015 ; Vol. 86, No. 1. pp. 38-44.
@article{d02be59c9e064ec1b22f69ce40e5dee0,
title = "Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis",
abstract = "Background Staging of disease severity is useful for prognosis, decision-making and resource planning. However, no commonly used, validated staging system exists for amyotrophic lateral sclerosis (ALS). Our purpose was to develop an ALS staging system (ALS Milano-Torino Staging) that captures the observed progressive loss of independence and function. Methods Clinical milestones in ALS progression were defined by loss of independence in four key domains on the ALS Functional Rating Scale (ALSFRS): swallowing, walking/self-care, communicating and breathing. Stages were defined as follows: stage 0, functional involvement but no loss of independence on any domain; stages 1-4, number of domains in which independence was lost; and stage 5, death. Staging criteria were applied to patients enrolled in a Quality of Care in ALS (QOC) study; endpoints included function (ALSFRS), quality of life (QOL; Short Form-36) and health service costs. Between-stage transition probabilities were assessed in the QOC study and in a second clinical study of lithium carbonate in ALS. Results 70/118 (59.3{\%}) participants in the QOC study progressed to higher stages of disease at 12 months compared with their baseline stage. Functional (ALSFRS) and QOL measures were inversely related to disease stage. Health service costs were directly related to increasing disease stages from 0 to 4 (p",
author = "Adriano Chi{\`o} and Hammond, {Edward R.} and Gabriele Mora and Virginio Bonito and Graziella Filippini",
year = "2015",
month = "1",
day = "1",
doi = "10.1136/jnnp-2013-306589",
language = "English",
volume = "86",
pages = "38--44",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis

AU - Chiò, Adriano

AU - Hammond, Edward R.

AU - Mora, Gabriele

AU - Bonito, Virginio

AU - Filippini, Graziella

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background Staging of disease severity is useful for prognosis, decision-making and resource planning. However, no commonly used, validated staging system exists for amyotrophic lateral sclerosis (ALS). Our purpose was to develop an ALS staging system (ALS Milano-Torino Staging) that captures the observed progressive loss of independence and function. Methods Clinical milestones in ALS progression were defined by loss of independence in four key domains on the ALS Functional Rating Scale (ALSFRS): swallowing, walking/self-care, communicating and breathing. Stages were defined as follows: stage 0, functional involvement but no loss of independence on any domain; stages 1-4, number of domains in which independence was lost; and stage 5, death. Staging criteria were applied to patients enrolled in a Quality of Care in ALS (QOC) study; endpoints included function (ALSFRS), quality of life (QOL; Short Form-36) and health service costs. Between-stage transition probabilities were assessed in the QOC study and in a second clinical study of lithium carbonate in ALS. Results 70/118 (59.3%) participants in the QOC study progressed to higher stages of disease at 12 months compared with their baseline stage. Functional (ALSFRS) and QOL measures were inversely related to disease stage. Health service costs were directly related to increasing disease stages from 0 to 4 (p

AB - Background Staging of disease severity is useful for prognosis, decision-making and resource planning. However, no commonly used, validated staging system exists for amyotrophic lateral sclerosis (ALS). Our purpose was to develop an ALS staging system (ALS Milano-Torino Staging) that captures the observed progressive loss of independence and function. Methods Clinical milestones in ALS progression were defined by loss of independence in four key domains on the ALS Functional Rating Scale (ALSFRS): swallowing, walking/self-care, communicating and breathing. Stages were defined as follows: stage 0, functional involvement but no loss of independence on any domain; stages 1-4, number of domains in which independence was lost; and stage 5, death. Staging criteria were applied to patients enrolled in a Quality of Care in ALS (QOC) study; endpoints included function (ALSFRS), quality of life (QOL; Short Form-36) and health service costs. Between-stage transition probabilities were assessed in the QOC study and in a second clinical study of lithium carbonate in ALS. Results 70/118 (59.3%) participants in the QOC study progressed to higher stages of disease at 12 months compared with their baseline stage. Functional (ALSFRS) and QOL measures were inversely related to disease stage. Health service costs were directly related to increasing disease stages from 0 to 4 (p

UR - http://www.scopus.com/inward/record.url?scp=84919730632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919730632&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2013-306589

DO - 10.1136/jnnp-2013-306589

M3 - Article

C2 - 24336810

AN - SCOPUS:84919730632

VL - 86

SP - 38

EP - 44

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 1

M1 - A10

ER -